Skip to content

Effect of A Self-Regulation Promoting Education Program on Adherence to Oral Anticancer Agents among Patients with Gastrointestinal Tract Cancer: A Randomized Controlled Trial

Effect of A Self-Regulation Promoting Education Program on Adherence to Oral Anticancer Agents among Patients with Gastrointestinal Tract Cancer: A Randomized Controlled Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400082958
Enrollment
Unknown
Registered
2024-04-11
Start date
2024-04-15
Completion date
Unknown
Last updated
2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastrointestinal tract cancer

Interventions

Control group:Routine care
Intervention group:Both routine care and four sessions of self-regulation promoting education program

Sponsors

The Nethersole School of Nursing, The Chinese University of Hong Kong
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1) age =18 years; 2) diagnosed with GI tract cancer, including esophagus, stomach, and colorectum cancer; 3) first time to receive first cycle of Capecitabine or S-1 treatment; 4) at least 4 cycles of OAA treatment are needed; 5) willing to participate.

Exclusion criteria

Exclusion criteria: 1) history of diagnosed mental or psychiatric problems; 2) currently participating in drug clinical trials; 3) medical certificate of being critically or terminally ill.

Design outcomes

Primary

MeasureTime frame
adherence to oral anticancer agents ;

Secondary

MeasureTime frame
Illness perception;Medication perception (e.g., medication belief, medication self-efficacy for appropriate medication use) ;Self-management behaviors on adherence to oral anticancer agents;Process evaluation (e.g.,eligibility rate, consent rate, attrition rate, intervention adherence,satisification and experience of receiving intervention);

Countries

China

Contacts

Public ContactChen Yongfeng; Shang Meimei

The Chinese University of Hong Kong; The Affiliated Cancer Hospital of Shandong First Medical University

1155184102@link.cuhk.edu.hk+852 9351 8670

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026